Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04YEW
|
||||
| Former ID |
DIB005258
|
||||
| Drug Name |
Tarafenacin
|
||||
| Synonyms |
SVT-40776; Muscarinic M3 receptor antagonist (overactive bladder), SALVAT
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Overactive bladder disorder [ICD9: 188, 596.51; ICD10:C67, N32.81] | Phase 2 | [1] | ||
| Company |
Laboratorios SALVAT SA
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H20F4N2O2
|
||||
| Canonical SMILES |
C1N2CC[C@@H]([C@H]1OC(=O)N(c1cc(ccc1)F)Cc1cc(c(c(c1)F)F<br />)F)CC2
|
||||
| CAS Number |
CAS 385367-47-5
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M3 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| Insulin secretion | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| Acetylcholine regulates insulin secretion | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01458197) A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.. U.S. National Institutes of Health. | ||||
| REF 2 | In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.